Showing results (141-150 of 149) with videos related to
Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
ACS Applied Materials & Interfaces|February 15, 2020
Graphene Quantum Dot Reinforced Electrospun Carbon Nanofiber Fabrics with High Surface Area for Ultrahigh Rate SupercapacitorsJing Zhao, Jiayao Zhu, Yutong Li, et al.Plos One|August 11, 2012
High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitisYali Cao, Jiajin Yang, Kerry Colby, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2024
Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker AnalysisWenya Wu, Yunsong Yang, Wentao Yang, et al.Journal of the American Society of Nephrology : JASN|May 28, 2011
DRB1*15 allele is a risk factor for PR3-ANCA disease in African AmericansYali Cao, John L Schmitz, Jiajin Yang, et al.International Journal of Epidemiology|March 19, 2014
Distribution of mammographic density and its influential factors among Chinese womenHongji Dai, Ye Yan, Peishan Wang, et al.JMIR Public Health and Surveillance|December 7, 2023
Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in ChinaShaohua Zhang, Jianbin Li, Ruonan Xu, et al.Scientific Reports|December 21, 2016
Preliminary effectiveness of breast cancer screening among 1.22 million Chinese females and different cancer patterns between urban and rural womenYubei Huang, Hongji Dai, Fengju Song, et al.Breast (Edinburgh, Scotland)|June 26, 2024
The features of male breast cancer in China: A real-world studyYuxuan Gao, Mengmeng Zhang, Gang Sun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2020
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III TrialJunjie Li, Keda Yu, Da Pang, et al.Pageof 15